AR and neoplasm: This splice variant has been detected in circulating tumor cells (CTCs) and is associated with resistance to androgen receptor axis-targeted agents (ARATs) such as enzalutamide and abiraterone (Antonarakis et al., 2016; Scher et al., 2016).